Vicarious Surgical Robotic System was added to Time Magazine’s list for the ‘Best Inventions of 2022’ — for reference; Apple’s iPhone was featured by Time in 2007 Best Inventions — NYSE: RBOT has moon-shot potential.


Vicarious Surgical Inc. (RBOT) Revolutionizing the Future of Surgical Medicine


Vicarious Surgical Inc.

NYSE stock symbol: RBOT

Share Price: ~$3.27 on NYSE

Market Cap: ~$400.15M USD

Shares Outstanding: ~$102.72 Million

Key statistics:

Company website:

The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

—— —— ——

Vicarious Surgical Inc. engages in developing and selling single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. It offers Vicarious System, a single-incision surgical robot for ventral hernia repair. Vicarious’ design is smaller, portable, and more affordable than other legacy systems.

Figure 1. (above) The Vicarious Surgical Robotic System (image source: company website). Specially trained surgeons wear a virtual reality (VR) headset to control the robotic surgical system. 360-degree vision and 56 total sensors (28 per arm) provide the equivalent of wrist, elbow, and shoulder joint dexterity, this gives surgeons extreme precision during operations.

The reason we are excited about establishing a long position in Vicarious is because the company is rapidly approaching real human trials. Below is an excerpt from the company’s corporate presentation about ‘expected roadmap’ for its technology:

In-short, Vicarious Surgical Inc. is close to revolutionizing the future of surgical medicine.

On November 17, 2022 released news ‘Vicarious Surgical Partners with Renowned Surgeon to Successfully Perform Two Cadaveric Ventral Hernia Procedures’, results relating to this news will be shared in the upcoming Investor Day (December 6, 2022).


Notice: Content above may contain forward-looking statements regarding future events that involve risk and uncertainties. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual events or results. Articles, excerpts, commentary and reviews herein are for information purposes and are not solicitations to buy or sell any of the securities mentioned.

Disclosure: The subject company of this article is not a client. Investor Opportunity has full editorial control of this article. The author has not been compensated to cover the subject company on Investor Opportunity. The author and/or its trading desk affiliate either owns now or plans on establishing a long position in the subject company.


Subscribe - News Letter

4 + 11 =

Share This